A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Trial Profile

A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma

Suspended
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2017 Planned primary completion date changed from 31 Oct 2017 to 28 Oct 2017.
    • 01 Jun 2017 Status changed from recruiting to suspended.
    • 24 May 2017 Planned number of patients changed from 34 to 35.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top